Skip to main content
WAVERLEY PHARMA INC. logo

WAVERLEY PHARMA INC. — Investor Relations & Filings

Ticker · WAVE ISIN · CA94357L1058 LEI · 254900VT8CXPPV1G5Q51 TSXV Manufacturing
Open in API
Filings indexed 96 across all filing types
Latest filing 2026-04-10 Proxy Solicitation & In…
Country CA Canada
Listing TSXV WAVE

About WAVERLEY PHARMA INC.

https://www.waverleypharma.com/

Waverley Pharma Inc. is a specialty biopharmaceutical company engaged in the research, development, and commercialization of safe, effective, and affordable therapeutics. The company primarily focuses on oncology, developing treatments such as poly ADP-ribose polymerase-1 (PARP-1) inhibitors for cancer. Waverley Pharma commercializes its pharmaceutical products in markets including the United Kingdom, evidenced by successful tenders for drugs like Capecitabine with NHS Scotland. Furthermore, the company operates a retail pharmacy in the United States, integrating pharmaceutical innovation with direct patient service operations.

Recent filings

Filing Released Lang Actions
Notice of the meeting and record date - English.pdf
Proxy Solicitation & Information Statement Classification · 85% confidence The document is a notice from the transfer agent detailing the upcoming Annual and Special Meeting of Security Holders, including record and meeting dates, location, and proxy delivery details. It serves to solicit proxy votes and inform shareholders ahead of the meeting rather than presenting financial results or regulatory compliance filings. This aligns with Proxy Solicitation & Information Statement materials (PSI).
2026-04-10 English
Notice of the meeting and record date - English.pdf
Regulatory Filings Classification · 80% confidence The document is a short notice to Canadian securities regulators from Computershare concerning the upcoming Annual and Special Meeting of Waverley Pharma Inc., including record dates, meeting date and location, and notice-and-access requirements. It does not provide full proxy materials or voting results and thus does not fit categories like AGM materials (AGM-R), Proxy Solicitation & Information Statement (PSI), or Declaration of Voting Results (DVA). As a miscellaneous regulatory announcement, it falls under the fallback category Regulatory Filings (RNS).
2026-04-10 English
Notice of the meeting and record date - English.pdf
Proxy Solicitation & Information Statement Classification · 89% confidence The document is a formal notice of the upcoming Annual and Special Meeting of Security Holders, providing record dates, meeting date, location, and proxy delivery details. It constitutes proxy solicitation materials rather than the AGM presentation itself. This aligns with the Proxy Solicitation & Information Statement category.
2026-04-10 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 85% confidence The document is a statutory certification (Form 52-109FV2) by the CFO certifying the issuer’s interim financial report and MD&A under Canadian NI 52-109. It is not the interim report itself (IR) nor an announcement of a report publication (RPA), but rather a standalone regulatory compliance filing. It does not fit any more specific category, so it falls under the general Regulatory Filings (RNS) category.
2025-05-22 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 75% confidence The document is a NI 52-109 venture issuer basic certificate – a statutory certification by the CFO regarding interim filings (interim financial report and interim MD&A). It is not the interim report itself, nor a summary of results, nor an announcement of a meeting or dividend. It is a compliance/regulatory form filed under Canadian securities rules, with no substantive financial statements or management discussion enclosed. Therefore, it best fits the fallback “Regulatory Filings” category (RNS).
2025-05-22 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 75% confidence The document is a Form 52-109FV2 ‘Certification of Interim Filings’ under Canadian NI 52-109, signed by the CEO certifying the interim financial report and interim MD&A. It is not the interim report itself (which would be an IR), nor an earnings release or management discussion. It’s a required regulatory compliance certificate that does not fit any more specific category, so it falls under the fallback Regulatory Filings category (RNS).
2025-05-22 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.